Trial · NCT01395914
Adverse events72
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 72
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Anamorelin HCl | 45 | 343 | 56 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo | 25 | 167 | 37 |
| other | Neutropenia | Blood and lymphatic system disorders | Anamorelin HCl | 18 | 343 | 21 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo | 8 | 167 | 8 |
| other | Asthenia | General disorders | Anamorelin HCl | 19 | 343 | 20 |
| other | Asthenia | General disorders | Placebo | 14 | 167 | 14 |
| other | Decreased appetite | Metabolism and nutrition disorders | Anamorelin HCl | 12 | 343 | 13 |
| other | Decreased appetite | Metabolism and nutrition disorders | Placebo | 10 | 167 | 10 |
| serious | Splenic rupture | Injury, poisoning and procedural complications | Anamorelin HCl | 1 | 343 | 1 |
| serious | Splenic rupture | Injury, poisoning and procedural complications | Placebo | 0 | 167 | 0 |
| serious | Colon cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Anamorelin HCl | 1 | 343 | 1 |
| serious | Colon cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 167 | 0 |
| serious | Neoplasm progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Anamorelin HCl | 16 | 343 | 16 |
| serious | Neoplasm progression | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 7 | 167 | 7 |
| serious | Tumour haemorrhage | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Anamorelin HCl | 1 | 343 | 1 |
| serious | Tumour haemorrhage | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 167 | 0 |
| serious | Angina unstable | Cardiac disorders | Anamorelin HCl | 1 | 343 | 1 |
| serious | Angina unstable | Cardiac disorders | Placebo | 0 | 167 | 0 |
| serious | Cardiopulmonary failure | Cardiac disorders | Anamorelin HCl | 0 | 343 | 0 |
| serious | Cardiopulmonary failure | Cardiac disorders | Placebo | 1 | 167 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01395914/events